JPRN-UMIN000015662已完成2 期
Phase II Study of Carboplatin+nab-Paclitaxel for Non-small Cell Lung Cancer with Interstitial Pneumonitis - Phase II Study of Carboplatin+nab-Paclitaxel for Non-small Cell Lung Cancer with Interstitial Pneumonitis
Yushima Lung Cancer Oncology Group(YLOG)0 个研究点目标入组 25 人开始时间: 2014年11月12日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
The 4-week modified regimen of carboplatin and nab-paclitaxel showed tolerable toxicity with favorable efficacy in NSCLC patients with ILD. This regimen may be an effective treatment option for patients in real clinical settings.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Active double cancer 2) Being suspected acute or sub-acute exacerbation of interstitial pneumonitis. Being experienced acute exacerbation of idiopathic interstitial pneumonia. 3) Receiving steroids or immunosuppressants within 3 month for interstitial pneumonia 4) Patiens has pleural effusion, pericardial effusion and ascites to need dranage 5) Serious complications as follows; History of uncontrollable angina pectoris, acute myocardial infarction or heart faliure, etc within 6 months History of cerebral infarction within 6 months Uncontrollable diabetes mellitus, hypertension and diarrhea Active infectious disease or suspected active infectious disease Other Serious complications (ileus, bleeding tendency , SVC syn. Varicella etc) 6) symptomatic brain metastasis 7) Pregnancy, breast feeding and suspected or wish of pregnancy. Men and women who declined contraception 8) Patients who have serious drug hypersensitivity reaction 9) Patients who have received a radiation therapy in chest 10) Having a schedule of operations 11) Patients whose participation in the trial is judged to be inappropriate because of psychiatric disease or psychiatric symptoms 12) Positive HBs antigen 13) Patients whose participation in the trial is judged to be inappropriate by the investigators
研究者
相似试验
已完成
2 期
Phase 2 study of Carboplatin plus nab-Paclitaxel for patients with PS 2 advanced NSCLC(TORG1426)on small cell lung cancerJPRN-UMIN000019458PO Thoracic Oncology Research Group42
已完成
2 期
Phase II study of Carboplatin + nab-Paclitaxel followed by nab-Paclitaxel with chemotherapy naive advanced Non- Small Cell Lung CancerChemotherapy naive non-small cell lung cancerJPRN-UMIN000015144Fukuoka University School of Medicine40
已完成
2 期
Phase II study of Carboplatin plus nab-Paclitaxel for advanced non-small cell lung cancer patients with interstitial lung diseaseAdvanced non-small cell lung cancer with interstitial lung diseaseJPRN-UMIN000012989Kanagawa Cardiovascular and Respiratory Center90
已完成
2 期
Phase II study of nab-paclitaxel and carboplatin with concurrent thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancerJPRN-UMIN000011681Gifu Municipal Hospital32
招募中
2 期
Phase II Study of Nab-paclitaxel and Carboplatin Plus Bevacizumab as First-Line Chemotherapy for Reccurent or stage IIIB and IV Nonsquamous Non-Small-Cell Lung Cancer (ALCT004)on-squamous non-small-cell lung cancerJPRN-UMIN000013310Kyorin University School of Medicine33